menu
    • menu
    [{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fezagepras","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Liminal BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fezagepras","moa":"GPR84","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Liminal BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Liminal BioSciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Fezagepras

    Menu

    Fezagepras

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Liminal BioSciences

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Liminal BioSciences

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezagepras

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepr...

                            Details : Analysis of the disproportionate metabolite data from the completed Phase 1 multi-ascending dose ("MAD") clinical trial revealed that PBI-4050 (fezagepras) primary metabolite was a glutamine conjugate.

                            Brand Name : PBI-4050

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 23, 2022

                            Lead Product(s) : Fezagepras

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Liminal BioSciences

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Liminal BioSciences

                            Canada arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fezagepras

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras

                            Details : Based on interim pharmacokinetic results from the ongoing fezagepras multiple ascending dose study, the Company has decided to stop its plans to move fezagepras into a Phase II clinical study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in H...

                            Brand Name : PBI-4050

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 28, 2021

                            Lead Product(s) : Fezagepras

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth